Recombinant Human Chondroitin Sulfate Proteoglycan 4 (CSPG4) Protein (His&Myc)

Name: Recombinant Human Chondroitin Sulfate Proteoglycan 4 (CSPG4) Protein (His&Myc)
Brand: Beta LifeScience
SKU: BLC-05144P
Availability: InStock

Greater than 85% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Chondroitin Sulfate Proteoglycan 4 (CSPG4) Protein (His&Myc) is produced by our Mammalian cell expression system. This is a protein fragment.
Purity	Greater than 85% as determined by SDS-PAGE.
Uniprotkb	Q6UVK1
Target Symbol	CSPG4
Synonyms	4732461B14Rik; AN2; AN2 proteoglycan; Chondroitin sulfate proteoglycan 4 (melanoma-associated); Chondroitin sulfate proteoglycan 4; Chondroitin sulfate proteoglycan NG2; Cspg4; Cspg4 chondroitin sulfate proteoglycan 4; CSPG4_HUMAN; HMW-MAA; HSN tumor-specific antigen; Kiaa4232; MCSP; MCSPG; MEL-CSPG; Melanoma chondroitin sulfate proteoglycan; Melanoma-associated chondroitin sulfate proteoglycan; MELCSPG; MSK16; NG2
Species	Homo sapiens (Human)
Expression System	Mammalian cell
Tag	N-10His&C-Myc
Target Protein Sequence	SLKGSQTLTVCPGSVQPLSSQTLRASSSAGTDPQLLLYRVVRGPQLGRLFHAQQDSTGEALVNFTQAEVYAGNILYEHEMPPEPFWEAHDTLELQLSSPPARDVAATLAVAVSFEAACPQRPSHLWKNKGLWVPEGQRARITVAALDASNLLASVPSPQRSEHDVLFQVTQFPSRGQLLVSEEPLHAGQPHFLQSQLAAGQLVYAHGGGGTQQDGFHFRAHLQGPAGASVAGPQTSEAFAITVRDVNERPPQPQASVPLRLTRGSRAPISRAQLSVVDPDSAPGEIEYEVQRAPHNGFLSLVGGGLGPVTRFTQADVDSGRLAFVANGSSVAGIFQLSMSDGASPPLPMSLAVDILPSAIEVQLRAPLEVPQALGRSSLSQQQLRVVSDREEPEAAYRLIQGPQYGHLLVGGRPTSAFSQFQIDQGEVVFAFTNFSSSHDHFRVLALARGVNASAVVNVTVRALLHVWAGGPWPQGATLRLDPTVLDAGELANRTGSVPRFRLLEGPRHGRVVRVPRARTEPGGSQLVEQFTQQDLEDGRLGLEVGRPEGRAPGPAGDSLTLELWAQGVPPAVASLDFATEPYNAARPYSVALLSVPEAARTEAGKPESSTPTGEPGPMASSPEPAVAKGGFLSFLEANMFS
Expression Range	1583-2224aa
Protein Length	Partial
Mol. Weight	73.2 kDa
Research Area	Cancer
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Proteoglycan playing a role in cell proliferation and migration which stimulates endothelial cells motility during microvascular morphogenesis. May also inhibit neurite outgrowth and growth cone collapse during axon regeneration. Cell surface receptor for collagen alpha 2(VI) which may confer cells ability to migrate on that substrate. Binds through its extracellular N-terminus growth factors, extracellular matrix proteases modulating their activity. May regulate MPP16-dependent degradation and invasion of type I collagen participating in melanoma cells invasion properties. May modulate the plasminogen system by enhancing plasminogen activation and inhibiting angiostatin. Functions also as a signal transducing protein by binding through its cytoplasmic C-terminus scaffolding and signaling proteins. May promote retraction fiber formation and cell polarization through Rho GTPase activation. May stimulate alpha-4, beta-1 integrin-mediated adhesion and spreading by recruiting and activating a signaling cascade through CDC42, ACK1 and BCAR1. May activate FAK and ERK1/ERK2 signaling cascades.
Subcellular Location	Cell membrane; Single-pass type I membrane protein; Extracellular side. Apical cell membrane; Single-pass type I membrane protein; Extracellular side. Cell projection, lamellipodium membrane; Single-pass type I membrane protein; Extracellular side. Cell surface.
Database References	HGNC: 2466 OMIM: 601172 KEGG: hsa:1464 STRING: 9606.ENSP00000312506 UniGene: PMID: 29291617 This study revealed that CSPG4 interacted with perlecan to support cell adhesion and actin polymerization and the data suggest a novel mechanism by which CSPG4 expressing cells might attach to perlecan-rich matrices so as those found in connective tissues and basement membranes. PMID: 29462330 Both tumor cell and vascular NG2 expression were shown to be present in a significant number of patients with colorectal cancer and this makes NG2 a double target for anti-tumor therapies. PMID: 28715802 NG2 may represent a promising target for the modulation of ICAM-1-mediated immune responses. PMID: 28964848 In addition to establishing the binding region for CSPG4, this work ascribes for the first time a role in TcdB CROPs in receptor binding and further clarifies the relative roles of host receptors in TcdB pathogenesis. PMID: 28842504 of NG2/CSPG4 rather than changes in CD44 or Ki-67 expression is associated with low overall survival in glioblastoma multiforme patients PMID: 28945172 The results indicate that CSPG4/NG2 has roles in regulating chondrosarcoma cell function in relation to growth, spread and resistance to chemotherapy. PMID: 27292772 A positive CSPG4 stain may be associated with an increased risk of metastasis and mortality from chordoma. PMID: 26689475 CSPG4 is a cell surface proteoglycan regulated by interleukin 11 in human endometrial epithelial cancer cells. the data suggest that CSPG4 inhibition may impair endometrial cancer progression by reducing cancer cell proliferation, migration and potentially epithelial-to-mesenchymal transition. PMID: 28098860 These data suggest the possible involvement of GD3 and NG2 in pre/pro-tumorigenic events occurring in the complex microenvironment of the tissue surrounding glioblastoma PMID: 26792897 the ratio of serum proteoglycan 4 to protease C1 inhibitor may be used for screening of early breast cancer. PMID: 26890881 The NG2 proteoglycan protects oligodendrocyte precursor cells against oxidative stress via interaction with OMI/HtrA2. PMID: 26340347 The up-regulation of NG2 is associated with poor prognosis in HCC. PMID: 26074703 Low CSPG4 expression is associated with pancreatic tumors. PMID: 24932730 These data are consistent with the concept that expression of inhibitory CSPG within the injury scar is an important impediment to regeneration but that NG2+ progenitors derived from ESNLCs can modify the microenvironment PMID: 25713464 NG2 expression in pediatric brain tumors differs depending upon type and, unlike adult glioma, includes expression on lower-grade tumors. PMID: 25503117 The results highlight an unprecedented, complex pattern of NG2/CSPG4 isoform expression in foetal and neoplastic CNS PMID: 24386429 MMP-13 overexpression or exogenous MMP-13 reduces anoikis by more effectively shedding NG2. PMID: 25166220 Reduced promoter methylation and increased expression of CSPG4 are associated with head and neck squamous cell carcinomas. PMID: 24740185 T-cells transduced with a CSPG4-specific chimeric antigen receptor inhibit the growth of CSPG4-expressing tumor cells both in vitro and in vivo. PMID: 24334762 Describe CSPG4-specific immunotoxin that kills rhabdomyosarcoma cells and binds to primary tumor tissues. PMID: 25016058 NG2 knockdown results in loss of beta1 integrin activation in endothelial cells, revealing a mechanism for NG2-dependent cross talk between pericytes and endothelial cells. PMID: 23925489 data suggest that locally produced CSPG4 stimulates human extravillous trophoblast migration and invasion and suggests that IL11 and LIF regulate villous cytotrophoblast differentiation towards the invasive phenotype at least in part via CSPG4. PMID: 23953863 NG2-Col VI interplay as putatively involved in the regulation of the cancer cell-host microenvironment interactions sustaining sarcoma progression PMID: 23559515 This study showed that high CSPG4 expression correlates with disease recurrence and overall survival in breast cancers. PMID: 24177010 Transgenic NG2-positive glia are identified as the major central nervous system cellular target of IL-17 in experimental autoimmune encephalomyelitis. PMID: 23995070 tThis study demonistrated taht human infants, Western blot analyses exhibited trends for lower NG2 levels in the germinal matrix and white matter of infants with Intraventricular hemorrhage relative to controls without Intraventricular hemorrhage. PMID: 23474192 cell polarity complexes as new effectors of NG2 signaling in the establishment of front-rear polarity PMID: 23804106 NG2-positive adipose stem cells loaded on scaffolds fabricate skeletal muscle tissue in vivo without the need of a myogenic pre-differentiation step in vitro. PMID: 23359523 NG2 mediates activation of Rho leading to amoeboid invasiveness in sarcoma cell line. PMID: 22699001 Although transgenic nestin-GFP-expressing progenitor cells share morphological and molecular markers with NG2-glia, they do not express other pericyte markers nor do they differentiate into the muscle lineage. PMID: 22999866 REVIEW outlines recent advances in our understanding of CSPG4-associated cell signaling, describing the central role it plays in melanoma tumor cell growth, motility, and survival, and explores how modifying CSPG4 function and protein-protein interactions may provide us with novel combinatorial therapies for the treatment of advanced melanoma PMID: 22004131 Cell surface P-selectin binding depends on CHST11 gene expression. CSPG4 serves as a P-selectin ligand through its CS chain and participates in P-selectin binding to the highly metastatic breast cancer cells. PMID: 21658254 Findings define the CSPG4-specific fully human scFv-FcC21 antibody as a candidate therapeutic agent to target the many types of tumors that express CSPG4. PMID: 22021902 High NG2 expression is associated with glioblastoma. PMID: 21798846 Functional and clinical relevance of chondroitin sulfate proteoglycan 4. PMID: 21070915 In regions of spinal cord neurodegeneration of amyotrophic lateral sclerosis model mice, NG2-positive cells exhibit enhanced proliferation and accelerated differentiation into oligodendrocytes but remained committed to the oligodendrocyte lineage. PMID: 21092857 Cells that express NG2 proteoglycan act predominantly as a reservoir of new oligodendrocytes in the demyelinated spinal cord. PMID: 21123584 Results showed the expression of MCSP and PRAME in conjunctival melanoma and benign conjunctival nevi and showed that MCSP and PRAME were differentially expressed in both and can help to differentiate the lesions diagnostically. PMID: 20805128 Staining intensity of HMW-MAA in acral lentiginous melanoma lesions was weaker than in superficial spreading melanoma where it was found to be higher than previously reported. PMID: 20448346 in squamous cell carcinoma of head and neck and in basal breast carcinoma, CSPG4 is expressed by cancer stem cells PMID: 20455858 Human skin aging is associated with reduced expression of the stem cell markers beta1 integrin and MCSP PMID: 19776755 identified a novel repeat named CSPG in the central ectodomain PMID: 12220645 Data suggest that MCSP is a novel marker for epidermal stem cells that contributes to their patterned distribution by promoting stem cell clustering. PMID: 14573520 MCSP coexpression with a subset of beta 1 integrin basal keratinocytes within the epidermis suggests that MCSP colocalizes with epidermal stem cells, MSCP expression within the hair follicle was more complex PMID: 15009727 MCSP may facilitate primary melanoma progression by enhancing the activation of key signaling pathways important for tumor invasion and growth. PMID: 15210734 PKC-alpha-mediated NG2 phosphorylation at Thr(2256) is a key step for initiating cell polarization and motility PMID: 15504744 MCSP/NG2 proteoglycan may be considered an important receptor mediating COL6-sarcolemma interactions, a relationship that is disrupted by the pathogenesis of UCMD muscle. PMID: 16169245 tumour cells can regulate both the function and structure of the host-derived tumour vasculature through NG2 expression PMID: 16253523 Co-expression and interaction of NG2 and galectin-3 in human glioma cells establish a molecular basis for the NG2/galectin-3 interaction. PMID: 16365873

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.